MP
ABMD

Manifold Partners’s Abiomed Inc ABMD Stock Holding History

Manifold Partners’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8,253
Closed -$782K – 44
2016
Q1 		$782K Buy
+8,253
New +$697K 0.7% 24

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Manifold Partners's ABMD Position: Q2 2016 in Review

Manifold Partners sold out of Abiomed Inc (ABMD) in Q2 2016, closing a stake of 8,253 shares — an estimated $782K sold.

Manifold Partners first reported a position in ABMD in Q1 2016 and held it in 1 quarter. The position peaked at $782K in Q1 2016. 297 funds tracked by Wall St. Rank hold ABMD as of Q2 2016.

  • Manifold Partners reported no remaining Abiomed Inc position as of Q2 2016 after selling out during the quarter.
  • Manifold Partners sold 8,253 Abiomed Inc shares in Q2 2016, an estimated $782K.
  • Manifold Partners first reported a position in Abiomed Inc in Q1 2016 and held it in 1 quarter.
  • Manifold Partners's Abiomed Inc position peaked at $782K in Q1 2016.
  • 297 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2016.

Based on Manifold Partners's 13F filing for Q2 2016, filed 1 Aug 2016.